| Active Ingredient(s) |
Conjugated equine estrogens (CEE) – a mixture of 16 estrogens, mostly estrone and equilin |
Estradiol (0.1 mg) – a natural estrogen |
| Form/Route |
Oral tablets, oral gel, transdermal patches, or vaginal tablets/gel |
Vaginal ring (inserted once a month) |
| Typical Uses |
Menopausal hot flashes, vaginal atrophy, prevention of osteoporosis; sometimes used off‑label |
Vaginal atrophy, dryness, dyspareunia, hot flashes; also for osteoporosis prevention |
| Dosing Frequency |
Daily (oral/patch) or weekly/biweekly (vaginal forms) |
Once per month (ring replaced after 3 weeks of use) |
| Systemic Absorption |
Significant systemic absorption → higher circulating estrogen levels |
Lower systemic absorption – primarily local vaginal effect |
| Risk of Endometrial Hyperplasia |
Requires concomitant progesterone if uterus is present |
Progesterone optional (often combined with a progestin) |
| Thromboembolic Risk |
Slightly higher when taken orally; transdermal is lower |
Lower than oral CEE; vaginal route reduces systemic risk |
| Breast Cancer Risk |
Modestly increased risk with combined therapy |
Lower risk, especially with vaginal route |
| Side Effects |
Nausea, headaches, breast tenderness, fluid retention |
Vaginal discharge, irritation, local bleeding, headaches |
| Compliance & Convenience |
Daily pill/patch or weekly gel; may be burdensome |
One monthly ring – high adherence |
| Insurance & Cost |
Widely covered; varies with formulation |
Typically covered; price may differ by brand |